The clinical significance of statistical significance

Oncologist

Volumn 13, Issue 11, 2008, Pages 1129-1133

  Kane, Robert C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Alpha; False positive inference; Statistical significance

Indexed keywords

CHEMOTHERAPY; EFFECT SIZE; NOTE; OUTCOME ASSESSMENT; POST HOC ANALYSIS; POWER ANALYSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

CLINICAL TRIALS, PHASE III AS TOPIC; ENDPOINT DETERMINATION; FALSE POSITIVE REACTIONS; HUMANS; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; SAMPLE SIZE; STATISTICS AS TOPIC;

EID: 56749107288     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0186     Document Type: Note

References (9)

1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). E9 Statistical Principles for Clinical Trials. Available at http://www.ich.org/cache/compo/276-254-1.html, accessed online September 10, 2008.
2. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
3. Bria E, Giannarelli D, Terzoli E. Treatment of resected non-small-cell lung cancer. N Engl J Med 2005;353:1523-1524.
4. Pisters K, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol 2005;23:3270-3278.
5. Crino L, Cappuzzo F, Zatloukal P et al. Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, phase II study. J Clin Oncol 2008;26: 4253-4259. [Note: An accompanying editorial discusses the paper's statistical conclusions as well.]
6. Lagakos SW. The challenge of subgroup analyses - reporting without distorting. N Engl J Med 2006;354:1667-1669.
7. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008;20:3913-3915.
8. Weiss GB, Bunce H 3rd, Hokanson JA. Comparing survival of responders and nonresponders after treatment: A potential source of confusion in interpreting cancer clinical trials. Controlled Clinical Trials 1983;4:43-52.
9. Goodman SN. Toward evidence-based medical statistics 1: The P value fallacy. Ann Internal Med 1999;130:995-1004.